Trial Profile
Multicenter, Single-Blinded, Randomized, Comparator-Controlled Noninferiority Trial to Compare the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Plasma (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Entegrion
- 06 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 15 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2019 Planned End Date changed from 30 Nov 2020 to 30 Jun 2021.